Prospectively, targeting mitochondria to enhance the anti-tumor function of CD8+ T cells presents a better further application perspective in tumor immunotherapy, especially in chimeric antigen receptor T cell (CAR-T) therapy. The gene discussed is CD8A; the disease is neoplasm.